Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

Cryptogenic Organizing Pneumonia: Between the Gold Standard Diagnosis Method or the Patient's Choice.

Related Articles

Cryptogenic Organizing Pneumonia: Between the Gold Standard Diagnosis Method or the Patient's Choice.

Chest. 2014 Mar 1;145(3 Suppl):217A

Authors: Zonzin G, Boechat C, de Souza G, Guerra S, das Virgens P, Abdalla J, Agostinho V

Abstract
SESSION TITLE: ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The cryptogenic organizing pneumonia (COP) is a disease characterized by impairment of alveolar ducts and terminal bronchioles with inflammation. It was previously known as bronchiolitis obliterans organizing pneumonia (BOOP). It affects men and women with the same incidence and may be secondary to infections, drugs or be a primary manifestation. This case report presents a patient with COP whose approach dispensed, in accordance with the patient, lung biopsy for diagnosis. Only clinical data,laboratorial and image exams were used to define the conduct.
CASE PRESENTATION: MCF, 55 years old, female, resident in the state of Rio de Janeiro and oligosymptomatic respiratory, exhibits extensive changes in pre-operatory chest X-ray performed during surgical risk for wrist fracture repair. She has a diagnosis of hypothyroidism and mild depression, which worsened after her father's death three monthis prior to her first symptons. It was requested a CT that showed diffuse alveolar consolidations, predominantly in iferior lingular segment and lower lobe of the left lung without pleural effusion and diffuse images of frosted glass, with slightly enlarged lymph nodes in the left pulmonary hilum. She had occasional episodes of low fever and frequent cough with yellowish expectoration with foamy aspect. Had three discrete episodes of hemoptysis. No pain reported. Was first treated empirically with antibiotics (a third generation quinolone), with no improvement. First pulmonary function tests presents FVC: 2,2/2,08L 0,69/0,65% (chg -4%), FEV1: 1,84/1,71L 0,72/0,66% (chg - 6%) , FEV1/FVC: 0,84/0,85 (chg 1%). The diffusion capacity (DLCO) was 11.9 mL/mmHg/min, 48% of predict. She was a social alcoholic and smoker(low level of smoking) and practiced physical exercises regularly for fifteen minutes per day. There was a slightly decrease in appetite. She was searched for rheumatologic diseases, with all tests negative for autoimmune disorders, including ANA, anti-RO and Waller Rose test. There were no collagen-vascular diseases. No microorganisms founded in sputum. No new medications or lung irritants identified in her clinical story. Normal glycemia and lipidogram, no anemia, no white blood cells total and differential abnormalities, normal renal and hepatic function. No changes in urinalysis and negative urine culture. Diagnostic hypothesis: Cryptogenic organizing pneumonia. It was suggested lung biopsy, which the patient refused vehemently, even by bronchoscopy. As an alternative it was stipulated therapeutic trial with 1 mg/kg/day of prednisone. She was previously tested for infectious diseases before the introduction of corticotherapy, with all tests negative. She evolved with rapid regression of all symptons and substantial improvement in the radiological (includes CT scan) and pulmonary function. The last evaluation, after 3 months of treatment exhibits: FVC: 2,45/2,53L 0,82/0,84% (chg 2%), FEV1: 2,47/2,25L 0,79/0,91% (chg 12%) , FEV1/FVC: 0,96/1,09% (chg 13%) , DLCO 27,1 mL/mmHg/min (109%). Totally assymptomatic in follow up.
DISCUSSION: Most interstitial lung diseases are indolent and can produce subacute or chronic symptoms that progress at various rates and are usually present for months to years before a diagnosis is established.The gold standard for diagnosis of COP is lung biopsy. Even transbronchial biopsy may be sufficient to establish it. Although, in elderly patients, debilitated or reluctant to biopsy, therapeutic trial with corticosteroids is acceptable, with a rigid follow up afterwards.
CONCLUSIONS: The patient improved dramatically after introduction of corticosteroid therapy, which has been decreasing gradually in posology. This case expresses an opportunity for choice by the patient, along with the physician and scientific evidence, to a personal approach for this disease.Reference #1: Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia. Respir Care. 2009.Reference #2: Oymak FS, Demirbas HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration. 2005;723:254-262Reference #3: Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organising pneumonia. Int J Tuberc Lung Dis. 2009DISCLOSURE: The following authors have nothing to disclose: Gilmar Zonzin, Christian Boechat, Gabriela de Souza, Silvio Guerra, Priscila das Virgens, Jamile Abdalla, Vinícius AgostinhoNo Product/Research Disclosure Information.

PMID: 24638382 [PubMed - in process]

Volatile organic compounds, new biomarkers in exhaled breath samples of lung cancer patients with and without chronic obstructive pulmonary disease.

Related Articles

Volatile organic compounds, new biomarkers in exhaled breath samples of lung cancer patients with and without chronic obstructive pulmonary disease.

Chest. 2014 Mar 1;145(3 Suppl):332A

Authors: Wagner C, Munoz MA, Jareño J, Gutierrez Ortega C, Aguilar Ros A, Carrillo Aranda B, Maldonado Sanz JA, Civera C, Callol L

Abstract
SESSION TITLE: Lung Cancer Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Tobacco smoke exposure is the main risk factor for the development of lung cancer (LC) and chronic obstructive pulmonary disease (COPD). In turn, COPD is a risk factor for the development of LC. Tobacco smoke contains a large number of free radicals, reactive oxygen species and reactive nitrogen species that increase oxidative stress. Damage to membrane lipids (lipid peroxidation) produces different volatile organic compounds (VOC) (aldehydes, carboxylic acids, etc.) that can be detected in exhaled breath.
AIMS: To determine whether there are differences between exhaled VOC in lung cancer patients with and without COPD.
METHODS:
METHODS: We collected exhaled air samples from 81 patients with LC (57 with COPD and 24 without COPD) via the breath sampler Bio-VOCTM FVC. The samples were analyzed by Thermal Desorption Gas Chromatography-Mass Spectrometry (TD GC-MS; Markes-Agilent Tech). SPSS® v-15 for Windows was used for statistical analysis. Informed consent was previously obtained in all cases.
RESULTS: The study included 81 mostly male (64/81) lung cancer patients, seventy per cent of which (n=57/81) also had COPD. The mean age was 66.5 (+/- 12.7 years) in the lung cancer group without COPD, and 69.3 (+/- 10.3) in the lung cancer group with COPD. Lung cancer patients with COPD were heavier smokers or ex-smokers in comparison to lung cancer patients without COPD. Among lung cancer patients with COPD squamous cell carcinoma and adenocarcinoma (33.3% each) were the most frequent histological types. We quantified amounts of hexanal, heptanal, octanal, nonanal, propanoic and nonanoic acid in exhaled breath samples. We observed statistically significant lower levels of propanoic acid in lung cancer patients without COPD in comparison to those with COPD (95% CI (1.7-13.1)). There were no differences in the content of exhaled propanoic acid between gender or lung cancer histology groups.
CONCLUSIONS: Propanoic acid in exhaled breath samples could be used to discriminate between lung cancer patients without and with COPD. Further studies are required to confirm this hypothesis. Supported by FIS (Formación en Investigación en Salud): PI07/1116; Neumomadrid 2008 and 2012, SEPAR (Sociedad Española de Neumonología y Cirugía Torácica) 2009/881 and 2012/135CLINICAL IMPLICATIONS: New biomrkers involved in lung cancer screening and other respiratory diseases (COPD)DISCLOSURE: The following authors have nothing to disclose: Carolin Wagner, Maria Angeles Munoz, Javier Jareño, Carlos Gutierrez Ortega, Antonio Aguilar Ros, Belen Carrillo Aranda, Jose Angel Maldonado Sanz, Concepcion Civera, Luis CallolVOCs are used in the evaluation of respiratory diseases such as lung cancer, COPD.

PMID: 24638494 [PubMed - in process]

Feasibility of microRNA Measurements in Routine Bronchoalveolar Lavage (BAL) and Bronchial Washings in Patients With Lung Cancer and Nonmalignant Pulmonary Diseases.

Related Articles

Feasibility of microRNA Measurements in Routine Bronchoalveolar Lavage (BAL) and Bronchial Washings in Patients With Lung Cancer and Nonmalignant Pulmonary Diseases.

Chest. 2014 Mar 1;145(3 Suppl):342A

Authors: Tufman A, Gamarra F, Kiefl R, Kaduthanam S, Kuner R, Huber R

Abstract
SESSION TITLE: Lung Cancer IISESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: Biomarkers are of importance for understanding the biology of disease and in diagnosis and treatment planning. MicroRNAs are short non-coding ribonucleotide chains which modify the expression of multiple genes and pathways. MicroRNAs in BAL and bronchial washings may prove useful as prognostic/ predictive and monitoring markers. However, microRNA measurements in these samples have yet to be established. We present data from a pilot study in which microRNAs implicated in lung cancer were measured.
METHODS: Lavage was performed as clinically indicated, filtered, and analysed according to standard clinical practice. The remaining fluid was frozen in 0.5-1.0ml aliquots at -20 °C. MicroRNAs were measured using qPCR. After precipitation and removal of the cellular fraction, two 200mcl aliquots per patient were analysed using six qPCR assays, each in duplicates. Spike-in miRNAs (C. elegans) were introduced before RNA extraction for standardized assessment of RNA recovery. In addition, RNA U6B was measured as a putative internal control RNA.
RESULTS: Lavage samples from four patients with sarcoidosis, lung adenocarcinoma, pulmonary fibrosis and chronic LTX rejection were analysed for miR-142 3p, miR-205, miR-486. Spike-in C. elegans miRNAs -39 and -54 were detected at a constant level in all samples. The RNA U6B was only weakly expressed. The target miRNAs were measurable in all samples. Technical replicates of the qPCR assays gave consistent results in all samples. Analyses of two aliquots from the same patient resulted in only minimal differences in measured miRNA levels. Measurements of miR-142-3p in the sarcoidosis aliquots showed slightly more deviation than in the remaining paired samples.
CONCLUSIONS: MicroRNAs could be identified reliably and reproducibly in all lavage samples. MiR-142 3p, miR-205 and miR-486 were selected based on their role in serum studies of NSCLC.
CLINICAL IMPLICATIONS: Further investigations of the significance of local microRNAs at diagnosis and during the course of treatment are ongoing.
DISCLOSURE: S. Kaduthanam: Grant monies (from sources other than industry): grant from federal ministry Ruprecht Kuner: Grant monies (from sources other than industry): grant from federal ministry The following authors have nothing to disclose: Amanda Tufman, Fernando Gamarra, Rosi Kiefl, Rudolf Huberresearch on potential biomarkers and pathogenesis of lung diseases.

PMID: 24638503 [PubMed - in process]

The Survey on the Current Status of Comorbidity About COPD (Chronic Obstructive Pulmonary Disease) Patients Burden in Rural Areas of Japan.

Related Articles

The Survey on the Current Status of Comorbidity About COPD (Chronic Obstructive Pulmonary Disease) Patients Burden in Rural Areas of Japan.

Chest. 2014 Mar 1;145(3 Suppl):392A

Authors: Uno T

Abstract
SESSION TITLE: COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Comorbidities with COPD (Chronic Obstructive Pulmonary Disease) is one of the most important problems. Previous reports suggested that systemic inflammation may be the link between COPD and comorbidities, but this issue is still low debated in Japan. Whatever the mechanism of comorbidities may be, it has important clinical, prognostic and therapeutic problems. In this study, investigated for the evaluation and measures about COPD burden patients of the current situation in rural area Japan. And also aimed that through comorbidities, contributes to improving patients care and COPD awareness.
METHODS: Subjects (n=40) in this survey conducted in who have regularly outpatient in a certain rural area hospital that had diagnosed COPD patients. Investigation strategy was using a questionnaire (Self fill out) survey and face-to-face methods. Main questionnaire items were sex, age, smoking history, smoking ratio, comorbidity type and the number of patients, awareness of COPD and Lung age.
RESULTS: COPD burden patient's characteristics were Male/Female: 95.0%/5.0%, Age: 70.1±10.3 [mean±SD]. 82.5% of patients had the comorbid disease. COPD burden patients, which accounts for the top with Hypertension (35.0%), Gastrointestinal diseases (27.5%), Diabetes (25.0%), had been comorbid, especially the upper gastrointestinal tract ulceration (. The most number of patient's comorbidities were 2 (35.0%, Age: 72.4±10.3 [mean±SD]). Maximum number were 6 (5.0%). Hypertension, Cancer were one of the most comorbidities. During the observation period, do the treatment of each disease, acute exacerbation of COPD was not observed. Also, no apparent rapid worsening of comorbidities.
CONCLUSIONS: In this study showed that many comorbidities were observed, we should sufficient management and re-recognized as a systemic diseases. Thus we were considered that necessary to build a better multidimensional treatment strategy for comprehensive assessment of COPD with comorbidities.
CLINICAL IMPLICATIONS: Comorbidities with COPD (Chronic Obstructive Pulmonary Disease) is a very important problem. We were considered that necessary to build a better multidimensional treatment strategy for comprehensive assessment of COPD with comorbidities
DISCLOSURE: The following authors have nothing to disclose: Tomoyasu UnoNo Product/Research Disclosure Information.

PMID: 24638549 [PubMed - in process]

Inhaled Colistin in Elderly Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa (PA) Bronchial Infection.

Related Articles

Inhaled Colistin in Elderly Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa (PA) Bronchial Infection.

Chest. 2014 Mar 1;145(3 Suppl):431A

Authors: Tabernero E, Gil P, Alkiza R, Garros J, Hernandez A, Artola JL

Abstract
SESSION TITLE: BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: To assess the effectiveness of inhaled colistin in elderly patients with bronchiectasis and chronic bronchial PA infection in reducing hospital readmissions
METHODS: Prospective, controlled and open label We included patients with HRCT diagnosed bronchiectasis and persistence of PA, after an acute exacerbation admission and appropriate antimicrobial therapy. All patients received education, physiotherapy and exercise training. Intervention group received also nebulized colistin 1mill UI twice a day for one year We collected data on demographics, clinical and functional characteristics, admissions in prior year and sputum microbiology. Patients were followed every two months for one year, evaluating readmissions, microbiological results, functional tests and deaths.
RESULTS: 39 patients were included, 20 received nebulized colistin and 19 conventional therapy. There were no differences between the two groups in baseline clinical and functional characteristics or previous hospital stay. Mean age was 77.7+/-5, Charlson index 2,85 and FEV1% 41,3+/-15. Five patients (25%) stopped the nebulized treatment because adverse effects. Pseudomonas aeruginosa was eradicated in 45% of the colistin treated patients and in only one of the control group (statistically significant) but at the end of the study year, there were no differences in the number of hospital admission (2,7+/-3 and 1,6+/-1,7) or days of stay (23+/-20 and 19+/-31) No differences in lung function or clinical symptoms were detected between both groups No significant changes were observed in PA antibiotic sensitivity or in sputum flora
CONCLUSIONS: More patients in the treatment group achieved Pseudomonas eradication, but we could not demonstrate benefits in clinical symptoms, lung function or use of healthcare resources in our elderly patients. Adverse effects were frequent.
CLINICAL IMPLICATIONS: Bronchiectasis is the end result of several different illnesses and a frequent cause of admission for elderly patients and chronic respiratory diseases. Although many guidelines recommend treatment with inhaled antibiotics in non cystic fibrosis bronchiectasis with PA chronic infection, there is limited evidence, and we could not find benefits with nebulized colistin in elderly patients with chronic severe obstruction. Further studies are needed in order to identify factors associated to response, or subgroups of patients with bronchiectasis and chronic infection with PA who benefit from (expensive) treatments with inhaled antibiotics
DISCLOSURE: The following authors have nothing to disclose: Eva Tabernero, Pilar Gil, Ramon Alkiza, Javier Garros, Anibal Hernandez, Juan Luis ArtolaNo Product/Research Disclosure Information.

PMID: 24638589 [PubMed - in process]

Search